^
    over3years
    A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients (clinicaltrials.gov)
    P1, N=26, Active, not recruiting, Gadeta B.V. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    IL6 (Interleukin 6)
    |
    GDT002
    over4years
    αβ-T Cells Engineered to Express γδ-T Cell Receptors Can Kill Neuroblastoma Organoids Independent of MHC-I Expression. (PubMed, J Pers Med)
    Of note, efficacy of TEG002 treatment was superior to donor-matched untransduced αβ-T cells or endogenous γδ-T cells. Our data suggest that TEG002 may be a promising novel treatment option for a subset of neuroblastoma patients.
    Journal • IO biomarker
    |
    IFNG (Interferon, gamma)
    |
    GDT002
    over4years
    A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients (clinicaltrials.gov)
    P1, N=26, Recruiting, Gadeta B.V. | Initiation date: Feb 2021 --> May 2021
    Clinical • Trial initiation date
    |
    IL6 (Interleukin 6)
    |
    GDT002
    5years
    A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients (clinicaltrials.gov)
    P1, N=26, Recruiting, Gadeta B.V. | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    IL6 (Interleukin 6)
    |
    GDT002
    over5years
    A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients (clinicaltrials.gov)
    P1, N=26, Not yet recruiting, Gadeta B.V.
    Clinical • New P1 trial
    |
    IL6 (Interleukin 6)
    |
    GDT002